GlassScriptPhysician profile
Komal Mehta
NPI 1932529617
$7,402.89
in general payments reported to CMS, 2019-2025
45 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.42 · 2020: $298 · 2021: $972 · 2022: $917 · 2023: $1,538 · 2024: $1,813 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,182.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,063.36 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $539.37 | 2020-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $529.40 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $493.88 | 2020-2025 | Tymlos |
| Lilly USA, LLC | $461.19 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $452.31 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $331.81 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.22 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $302.56 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $293.15 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $288.49 | 2023-2025 | Unithroid |
| Abbvie INC. | $263.03 | 2019-2025 | |
| Corcept Therapeutics | $178.66 | 2019-2022 | |
| Dexcom, INC. | $163.35 | 2022-2024 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $157.31 | 2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $144.12 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $117.77 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $115.87 | 2023-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $110.21 | 2023-2025 | |
| Cequr Corporation | $86.95 | 2022-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $82.48 | 2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $77.31 | 2024-2025 | |
| Horizon Therapeutics Plc | $76.28 | 2021-2023 | Tepezza |
| Acella Pharmaceuticals, LLC | $75.80 | 2023-2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $63.84 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $63.35 | 2023-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $51.09 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $50.31 | 2025 | Imcivree |
| Amphastar Pharmaceuticals, INC. | $48.58 | 2024 | |
| Ibsa Pharma INC. | $48.54 | 2023-2024 | Tirosint, Licart, Tirosint |
| Vivus LLC | $46.80 | 2021-2024 | Qsymia |
| Inspire Medical Systems, INC. | $33.30 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $25.61 | 2022 | |
| Neurocrine Biosciences, INC. | $25.34 | 2024 | |
| Sandoz INC. | $25.09 | 2024 | |
| Chiesi USA, INC. | $22.96 | 2025 | Mycapssa |
| Astellas Pharma US INC | $22.91 | 2023 | Veozah |
| Embecta Corp. | $22.29 | 2024 | |
| Echosens North America, INC. | $22.06 | 2024 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.88 | 2023 | Cycloset |
| Almatica Pharma LLC | $18.25 | 2025 | Teriparatide |
| Pfizer INC. | $17.41 | 2024 | |
| Amarin Pharma, INC. | $16.86 | 2021 | |
| Kyowa Kirin, INC. | $15.38 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $15.16 | 2025 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.